^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MHB088C
i
Other names: MHB088C
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Minghui Pharma
Drug class:
Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
Related drugs:
2years
Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=48, Not yet recruiting, Minghui Pharmaceutical Pty Ltd
New P1/2 trial • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
MHB088C
Share via
